Immuneering (NASDAQ:IMRX) Given “Buy” Rating at Chardan Capital

Immuneering (NASDAQ:IMRX)‘s stock had its “buy” rating reaffirmed by research analysts at Chardan Capital in a research report issued on Wednesday,Benzinga reports. They presently have a $13.00 price objective on the stock. Chardan Capital’s target price suggests a potential upside of 450.85% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on the stock. Morgan Stanley cut shares of Immuneering from an “equal weight” rating to an “underweight” rating in a research report on Friday, December 13th. Needham & Company LLC restated a “buy” rating and set a $15.00 price objective on shares of Immuneering in a report on Tuesday. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $12.80.

Immuneering Stock Performance

IMRX opened at $2.36 on Wednesday. Immuneering has a one year low of $1.00 and a one year high of $7.68. The stock has a market cap of $73.28 million, a price-to-earnings ratio of -1.20 and a beta of -0.34. The stock’s 50 day moving average price is $2.04 and its 200-day moving average price is $1.77.

Institutional Trading of Immuneering

Hedge funds have recently bought and sold shares of the stock. Vontobel Holding Ltd. bought a new position in shares of Immuneering in the 3rd quarter worth $25,000. Corsair Capital Management L.P. purchased a new stake in shares of Immuneering during the third quarter valued at about $25,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Immuneering in the 2nd quarter valued at about $44,000. XTX Topco Ltd grew its position in shares of Immuneering by 37.3% in the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock worth $44,000 after buying an additional 9,274 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new position in shares of Immuneering during the 2nd quarter worth approximately $67,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.